Quest Diagnostics Incorporated (DGX) |
| 206 -1.35 (-0.65%) 07-14 16:00 |
| Open: | 202.8 |
| High: | 208.52 |
| Low: | 201.13 |
| Volume: | 865,885 |
| Market Cap: | 22,803(M) |
| PE Ratio: | 20.32 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 254.99 |
| Resistance 1: | 218.31 |
| Pivot price: | 208.47 |
| Support 1: | 202.08 |
| Support 2: | 192.05 |
| 52w High: | 219.2 |
| 52w Low: | 164.65 |
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
| EPS | 9.050 |
| Book Value | 66.360 |
| PEG Ratio | 1.62 |
| Gross Profit | 33.875 |
| Profit Margin (%) | 9.08 |
| Operating Margin (%) | 14.20 |
| Return on Assets (ttm) | 6.3 |
| Return on Equity (ttm) | 14.5 |
Tue, 14 Jul 2026
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus - TradingView
Tue, 14 Jul 2026
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD) - The Globe and Mail
Tue, 14 Jul 2026
Quest Diagnostics stock holds steady on a broad health care backdrop - Ad-hoc-news.de
Mon, 13 Jul 2026
Baird Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $236 - Moomoo
Sat, 11 Jul 2026
Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability - ChartMill
Sat, 11 Jul 2026
Quest Diagnostics (DGX) Proxy filing Summary - Quartr
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |